# FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

> **NCT02890355** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 123 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage IV Pancreatic Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT02890355
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-01
- **Primary completion:** 2019-05-01
- **Final completion:** 2026-03-17
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890355, "FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02890355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*